Investors include an undisclosed global strategic investor, ALIVE VC and Agriline

投资者包括未披露的全球战略投资者ALIVE VC和Agriline

MISGAV, Israel, Feb. 14, 2024 /PRNewswire/ -- Vessi Medical Ltd. ('Vessi') announced today that it has closed a Series A financing round of $16.5 million for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer ('NMIBC'). Leading investors in the round are an undisclosed global strategic investor, ALIVE- Israel HealthTech Fund, and Agriline, a trust of which UK investor Vincent Tchenguiz is a discretionary beneficiary, joining The Trendlines Group..

以色列米斯加夫，2024年2月14日/PRNewswire/--Vessi Medical Ltd.（“Vessi”）今天宣布，它已经完成了一轮1650万美元的融资，用于治疗非肌肉浸润性膀胱癌（“NMIBC”）的冷冻治疗技术。这一轮的主要投资者是未披露的全球战略投资者ALIVE-Israel HealthTech Fund和Agriline，英国投资者Vincent Tchenguiz是该信托的全权受益人，加入了Trendlines Group。。

Vessi's minimally invasive solution for NMIBC provides a new therapeutic alternative to Transurethral Resection of Bladder Tumor ('TURBT'), the costly leading invasive surgical first-line therapy. NMIBC is defined as a cancer on the surface of the inner lining of the bladder. Physical symptoms include problems urinating, pain and blood in the urine, and sexual dysfunction, all leading to a significant decrease in quality of life.

Vessi针对NMIBC的微创解决方案为经尿道膀胱肿瘤切除术（TURBT）提供了一种新的治疗替代方案，TURBT是一种昂贵的领先侵入性外科一线治疗方法。NMIBC被定义为膀胱内壁表面的癌症。身体症状包括排尿困难、尿中疼痛和血液以及性功能障碍，所有这些都会导致生活质量显着下降。

The company's bladder-specific proprietary cryotherapy has the potential for significantly improving quality of life; the technology has been successfully used in a first in human study..

该公司的膀胱特异性专有冷冻疗法具有显着改善生活质量的潜力；该技术已成功应用于首次人体研究。。

Vessi Medical Founder & CEO Eyal Kochavi, commented, 'We are thrilled to announce the closing of this round, especially during this challenging time. The participation of a global strategic investor in this round is a huge show of confidence in Vessi's achievements and potential. The financing led by ALIVE will support expanding Vessi's R&D capabilities, clinical studies in Israel and the U.S., and regulatory clearance, enabling us to achieve our goal of bringing Vessi's treatment for NMIBC to patients and physicians to reduce side effects, improve patient outcomes, and lower health care costs.'.

Vessi Medical创始人兼首席执行官埃亚尔·科查维（EyalKochavi）评论道：“我们很高兴宣布本轮谈判结束，特别是在这个充满挑战的时刻。全球战略投资者参与本轮投资，是对Vessi成就和潜力的巨大信心。由ALIVE牵头的资金将支持扩大Vessi的研发能力，在以色列和美国的临床研究以及监管许可，使我们能够实现将Vessi治疗NMIBC带给患者和医生的目标，以减少副作用，改善患者预后，降低医疗保健成本。”。

Prof. Rafi Beyar, ALIVE's Managing General Partner, who will join the BOD of Vessi, commented, 'The investment in Vessi is an excellent demonstration of ALIVE's strategy to invest in category technology leaders alongside global partners with strategic value, targeting in this case the treatment of bladder cancer with a superior cryotherapy solution.'  Michel Habib, ALIVE's Managing General Partner, added, 'The funds secured thanks to the investment partnership with a global strategic investor will allow Vessi's team to focus on executing its clinical and regulatory plan, and efficiently achieve value creating milestones.'   .

ALIVE的常务普通合伙人拉菲·贝亚尔教授（RafiBeyar）将加入Vessi的董事会，他评论道：“对Vessi的投资是ALIVE与具有战略价值的全球合作伙伴一起投资类别技术领导者的战略的极好证明，在这种情况下，目标是用优质的冷冻疗法解决方案治疗膀胱癌。”ALIVE的管理普通合伙人米歇尔·哈比卜（MichelHabib）补充说，“由于与全球战略投资者的投资伙伴关系，获得的资金将使Vessi的团队能够专注于执行其临床和监管计划，并有效实现创造价值的里程碑。”。

Vincent Tchenguiz, owner of Consensus Business Group and Agriline discretionary beneficiary: 'Positioned at the vanguard of technological advancement, Vessi Medical's cutting-edge cryotherapy for NMIBC heralds a transformative shift in both cancer care and health economics.

共识商业集团（Consensus Business Group）的所有者兼Agriline全权受益人文森特·琴奎兹（Vincent Tchenguiz）：“维西医疗（Vessi Medical）针对NMIBC的尖端冷冻疗法处于技术进步的前沿，预示着癌症护理和卫生经济学的变革性转变。

Our investment is a testament to our confidence in Vessi's revolutionary potential to not only enhance patient outcomes but also to redefine care standards, alleviate suffering, and spearhead the development of more compassionate and efficacious treatment modalities. The fusion of groundbreaking science and the strategic investment of a global player, ALIVE, and Agriline constitutes a strong and solid mix that can greatly contribute to the company's success.

我们的投资证明了我们对Vessi的革命性潜力的信心，该潜力不仅可以提高患者的治疗效果，还可以重新定义护理标准，减轻痛苦，并带头开发更具同情心和有效的治疗方式。开创性的科学与全球参与者ALIVE和Agriline的战略投资相结合，构成了强大而坚实的组合，可以极大地促进公司的成功。

Vessi's promise to catalyze improvements and innovation in healthcare heralds an exciting era in NMIBC treatment.'.

Vessi承诺促进医疗保健的改进和创新，预示着NMIBC治疗将进入一个激动人心的时代。”。

About Vessi Medical

关于Vessi Medical

Vessi Medical is an Israel-based urology medical device company that has developed an innovative, IP-protected cryospray system, purposely designed for hollow & humid organs, a novel approach for the treatment of Non Muscle Invasive Bladder Cancer (NMIBC). Vessi's founding investor is The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), with the support of the Israel Innovation Authority..

Vessi Medical是一家总部位于以色列的泌尿外科医疗器械公司，该公司开发了一种创新的IP保护冷冻喷雾系统，专门为中空和潮湿器官设计，这是一种治疗非肌肉浸润性膀胱癌（NMIBC）的新方法。Vessi的创始投资者是趋势线集团（SGX:42T）（OTCQX:TRNLY），得到以色列创新局的支持。。

Contact:

联系人：

Eyal Kochavi, CEO Vessi Medical [email protected]

Vessi Medical首席执行官Eyal Kochavi[受电子邮件保护]

SOURCE Vessi Medical

来源Vessi Medical